On August 9, 2024, NexImmune, Inc. conducted a special meeting of stockholders in a virtual format to vote on the dissolution and subsequent liquidation of the company. The meeting saw a quorum with 55.18% of the voting power present, based on the record date of June 11, 2024. The stockholders approved the dissolution and liquidation plan with 1,145,369 votes in favor, 344,758 against, and 23,226 abstentions. Additionally, a second proposal to adjourn the meeting to a later date, if necessary, to solicit more proxies in case of insufficient votes for the first proposal, was also approved with 1,322,991 votes for, 120,736 against, and 69,626 abstentions. The company has cautioned that trading in its securities is highly speculative and poses substantial risks, advising extreme caution with respect to investments in its securities.

On August 9, 2024, NexImmune, Inc. conducted a special meeting of stockholders in a virtual format to vote on the dissolution and subsequent liquidation of the company. The meeting saw a quorum with 55.18% of the voting power present, based on the record date of June 11, 2024. The stockholders approved the dissolution and liquidation plan with 1,145,369 votes in favor, 344,758 against, and 23,226 abstentions. Additionally, a second proposal to adjourn the meeting to a later date, if necessary, to solicit more proxies in case of insufficient votes for the first proposal, was also approved with 1,322,991 votes for, 120,736 against, and 69,626 abstentions. The company has cautioned that trading in its securities is highly speculative and poses substantial risks, advising extreme caution with respect to investments in its securities.